FDA Revision Of "Fee Matrix" For Civil Money Penalties Requested By HIMA
This article was originally published in The Gray Sheet
Executive Summary
FDA should modify the point system outlined in its proposed "Fee Matrix" for calculating civil money penalties (CMPs), the Health Industry Manufacturers Association suggests in Sept. 7 comments to FDA.
You may also be interested in...
FDA's Draft Civil Money Penalty Reduction Policy Needs Clarifications - HIMA
FDA's draft policy on civil monetary penalty reductions for small entities is at odds with Sec. 303(f) of the Food Drug & Cosmetic Act because it could be used to exclude certain firms that have violated agency rules within the last five years, the Health Industry Manufacturers Association maintains.
"Fee Matrix" Will Determine Device Civil Money Penalties - Draft Guidance
FDA's draft policy on civil monetary penalties (CMPs) under the Safe Medical Devices Act of 1990 includes a "fee matrix" to help insure the consistency of assessments against chronic and repeat violators of the agency's good manufacturing procedures and premarket notification regulations.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.